AC Immune and J&J Advance Tau-Targeting Alzheimer’s Vaccine
Encouraging Early Efficacy Signs
Executive Summary
AC Immune has seen two big disappointments in its Alzheimer’s pipeline this year, but its partner Johnson & Johnson has put its faith in a novel vaccine-like approach to targeting the disease.
You may also be interested in...
Eisai/Biogen’s Lecanemab Effective Across Endpoints, But Will Safety Limit Use?
Alzheimer’s patients treated with the amyloid protofibril-clearing antibody had slower disease progression compared to placebo, with differences increasing over time. Safety concerns, however, are growing.
Failure Of Roche’s Nine-Year Alzheimer’s Prevention Study Disappointing, But No Surprise
The ambitious prevention study in people with a nearly 100% chance of developing Alzheimer’s disease has failed, and attention will now switch to trial readouts for the next generation of beta-amyloid targeting candidates.
After ‘Puzzling’ Results For Antibody Drug, AC Immune’s Alzheimer’s Vaccine Shows Early Promise
Another hard-to-explain result in Alzheimer’s, with AC Immune claiming the first ever validation of anti-tau therapy, but others are more circumspect.